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Arginase 1 (Arg1) and indoleamine 2,3-dioxygenase
1 (IDO1) are immunoregulatory enzymes catalyzing
the degradation of L-arginine and L-tryptophan,
respectively, resulting in local amino acid depriva-
tion. In addition, unlike Arg1, IDO1 is also endowed
with non-enzymatic signaling activity in dendritic
cells (DCs). Despite considerable knowledge of their
individual biology, no integrated functions of Arg1
and IDO1 have been reported yet. We found that
IDO1 phosphorylation and consequent activation of
IDO1 signaling in DCswas strictly dependent on prior
expression of Arg1 and Arg1-dependent production
of polyamines. Polyamines, either produced by DCs
or released by bystander Arg1+ myeloid-derived
suppressor cells, conditioned DCs toward an IDO1-
dependent, immunosuppressive phenotype via acti-
vation of the Src kinase, which has IDO1-phosphory-
lating activity. Thus our data indicate that Arg1 and
IDO1 are linked by an entwined pathway in immuno-
metabolism and that their joint modulation could
represent an important target for effective immuno-
therapy in several disease settings.
INTRODUCTION
Over the course of evolution, the catabolic pathways of L-tryp-
tophan (Trp) and of L-arginine (Arg) have evolved to be primary
regulatory nodes in the control of immune responses (Grohmann
and Bronte, 2010; Murray, 2016). Trp, an essential amino acid for
mammals, is a substrate for indoleamine 2,3-dioxygenase
1 (IDO1), which catalyzes the first, rate-limiting step in the kynur-Immunity 46, 233–244, Febr
This is an open access article under the CC BY-Nenine pathway, leading to Trp depletion and the production of a
series of immunoregulatory molecules collectively known as ky-
nurenines (Grohmann et al., 2003b; Mellor andMunn, 2004; Puc-
cetti and Grohmann, 2007a). Both effects—namely, Trp starva-
tion and kynurenine production—are involved in the conversion
of naive CD4+ T cells into Foxp3+ regulatory T (Treg) cells (Fallar-
ino et al., 2006; Puccetti and Grohmann, 2007a). Moreover, the
main IDO1 catalytic product, L-kynurenine (Kyn), has immuno-
regulatory effects in the absence of Trp starvation, via activation
of the Aryl hydrocarbon Receptor (AhR) (Grohmann and Puc-
cetti, 2015; Platten et al., 2012).
High IDO1 expression and catalytic activity occur in dendritic
cells (DCs) in response to the cytokine interferon-g (IFN-g) (Groh-
mann et al., 2003b). In DCs stimulated with transforming growth
factor b (TGF-b), IDO1 becomes instead phosphorylated in its
immune-based inhibitory tyrosine motifs (ITIMs), so to mediate
intracellular signaling events in a self-sustaining feedforward
loop that leads to durable immunoregulatory effects (Bessede
et al., 2014; Pallotta et al., 2014; Pallotta et al., 2011; Volpi
et al., 2016). The composite mode of action of IDO1 may well
explain its being recognized as an authentic regulator of immu-
nity under several physiopathologic conditions (Orabona and
Grohmann, 2011; Puccetti and Grohmann, 2007a).
Arg is a semi-essential amino acid, i.e., it is required by mam-
mals only under special circumstances, such as immune re-
sponses. In immunecells, Arg is activelymetabolizedby arginase
1 (Arg1) or Arg2 to produce urea and L-ornithine (Orn) or it is used
for protein biosynthesis (Wu and Morris, 1998). Moreover, nitric
oxide synthases use Arg to make nitric oxide—a key anti-micro-
bial gas and signaling molecule—and L-citrulline (Bronte and Za-
novello, 2005). Arg consumption by Arg1, rather than Arg2 or ni-
tric oxide synthases, represents awell-known immunoregulatory
mechanism exploited by M2 macrophages (Murray, 2016; Sica
and Mantovani, 2012), as well as myeloid-derived suppressor
cells (MDSCs) in tumoral settings (Gabrilovich and Nagaraj,
2009; Marigo et al., 2008). Conversely, the immunoregulatoryuary 21, 2017 ª 2017 The Author(s). Published by Elsevier Inc. 233
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Arg1 and IDO1 Are Co-expressed
in DCs Stimulated with TGF-b
(A) Real-time PCR analysis of Arg1 and Ido1
transcripts in DCs stimulated for 3 or 18 hr with
IL-4, IFN-g, TGF-b, IL-4 plus TGF-b, or IFN-g plus
TGF-b normalized to the expression of Gapdh
(encoding glyceraldehyde phosphate dehydroge-
nase) and presented relative to results in untreated
cells (dotted line, 1-fold).
(B) Arg1 and IDO1 immunoblot analysis of cell ly-
sates from DCs incubated with IL-4, IFN-g, TGF-b,
IL-4 plus TGF-b, IFN-g plus TGF-b, or medium
alone (untreated, unt) for 24 hr.
(C) Arg1 and (D) IDO1 activity measured in terms
of urea in cell lysates and L-kynurenine in cell
supernatants, respectively, of DCs incubated as
in (B).
*p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test;
cytokine-treated versus untreated samples). All
data are from one experiment representative of
three (A–D; means ± SD of triplicates in A, C,
and D).role of catalytic products via Arg1 activity (urea andOrn) has been
unclear (Grohmann andBronte, 2010). T helper 2 (Th2) cytokines,
such as interleukin-4 (IL-4) and IL-13, represent efficient inducers
of Arg1 expression (Gabrilovich and Nagaraj, 2009; Marigo et al.,
2008; Sica and Mantovani, 2012), although TGF-b has also been
shown to upregulate the enzyme, at least in rat peritoneal macro-
phages (Boutard et al., 1995). Besides its involvement in mouse
dendritic cell (DC) differentiation (Yang et al., 2015), the biology
of Arg1 in DCs is still obscure. As a whole, the bulk of the data
on Arg1 and IDO1 would suggest that the two amino-acid meta-
bolic enzymes might operate in quite distinct spatial (i.e., cells)
and mechanistic modes, namely via either amino acid starvation
itself (as is the case for Arg1) or via the combined effects of immu-
noregulatory Kyn and signaling activity (IDO1). This suggests that
the enzymes have separate functions (to possibly cope with
distinct environmental needs) and/or have evolved to comple-
ment, rather than integrate, each other.
DCs integratemultiple signals andmechanisms in order to pro-
mote either adaptive immunity or immune tolerance in response
to specific conditions, such as distinct types of cytokinic milieu
(BanchereauandSteinman, 1998;Macagnoet al., 2007).Byusing
themain cytokines capable of inducing thosemetabolic enzymes
(i.e., IFN-g, IL-4, and TGF-b), we here investigated whether Arg1234 Immunity 46, 233–244, February 21, 2017and IDO1 were co-expressed in DCs and
what the functional meaning—if any—of
their co-expression would be. We found
that (1) TGF-b, but neither IL-4, IFN-g,
nor combination thereof, will induce both
Arg1and IDO1 inDCs,withArg1beingup-
regulated before IDO1; (2) Arg1 activity is
absolutely required for IDO1-dependent
signaling events as initiated by TGF-b;
(3) a polyamine—spermidine, resulting
from Orn decarboxylation—can replace
TGF-b in the activation of the Src kinase
that phosphorylates IDO1 and trigger
immunosuppressive IDO1 signaling; and(4) DCs can be conditioned by Arg1+ MDSCs to express an
IDO1-dependent immunosuppressive phenotype.
RESULTS
TGF-b Induces Co-expression of Arg1 and IDO1 in DCs
We investigated the expression and catalytic activity of Arg1 and
IDO1 in splenic CD11c+ DCs stimulated with IL-4 (i.e., the main
Arg1 inducer), IFN-g, or TGF-b, both of which are IDO1 inducers.
Combinations of TGF-b and IL-4 or IFN-g were also tested. In
accordance with previous data (Pallotta et al., 2011), transcript
analysis at 3 and 18 hr of cytokine incubation revealed that
both IFN-g and TGF-b upregulated Ido1 expression, with IFN-g
inducing the IDO1-encoding gene to a higher extent and more
rapidly than TGF-b (Figure 1A). By contrast, IL-4 did not increase
Ido1, but it did induceArg1 expression (>7-fold increase at 3 hr of
stimulation). No modulatory effect could be observed for IFN-g
on Arg1 expression. In contrast, TGF-b upregulated Arg1 in a
more intense fashion and with faster kinetics than Ido1. Negli-
gible transcript expression for Arg2 and Nos2 (coding for the
inducible nitric oxide synthase) could be observed in either unsti-
mulated or TGF-b-stimulated DCs (data not shown). DC incuba-
tion with TGF-b plus IL-4 resulted in a synergistic effect on Arg1
AC
B Figure 2. Arg1 Expression Is Necessary for
IDO1 Induction by TGF-b in DCs
(A) Kinetic analysis of Arg1 and Ido1 transcripts in
DCs from wild-type (WT) mice after incubation
with TGF-b for different times (indicated).
(B) Kinetic analysis of Ido1 and Arg1 transcripts in
DCs from Itgax-cre;Argfl/fl animals prior to incu-
bation with TGF-b or IFN-g for different times. DCs
from WT animals were used as control for IFN-g
stimulation. In (A) and (B), data are normalized and
presented as in Figure 1A.
(C) Kynurenine concentrations in supernatants of
DCs from Itgax-cre;Arg1fl/fl and WT animals incu-
bated with TGF-b, IFN-g, or medium alone for
24 hr.
*p < 0.05; **p < 0.01; and ***p < 0.001 (Student’s
t test; cytokine-treated versus untreated samples).
All data are from one experiment representative of
three (means ± SD of triplicates). Please see also
Figure S1.upregulation (>12- and 20-fold increase at 3 and 18 hr, respec-
tively) but in no induction of Ido1. On combining TGF-b with
IFN-g, no incremental effect over that of IFN-g alone was
observed at 3 hr and impaired upregulation of Ido1 expression
by TGF-b would instead occur at 18 hr.
We next evaluated whether the differential modulation of Arg1
and IDO1 could also be observed at the level of protein expres-
sion and catalytic activity. Immunoblot analyses with anti-Arg1
and anti-IDO1 antibodies on lysates of DCs—subjected to the
same treatments as in Figure 1A but for 24 hr—confirmed the
real-time PCR experiments, i.e., IL-4 and IFN-g induce only
Arg1 and IDO1, respectively, whereas TGF-b alone, but not in
combination with IL-4 or IFN-g, upregulated protein expression
of both enzymes (Figure 1B). Similarly, the enzymic activities of
both Arg1 (measured in terms of urea contents in cell lysates;
Figure 1C) and IDO1 (in terms of Kyn concentrations in culture
supernatants; Figure 1D) were significantly upregulated at
24 hr by TGF-b but not IL-4, IFN-g, or combinations thereof.
Therefore, these data showed that Arg1 can be expressed in
DCs, specifically in response to IL-4 and/or TGF-b, and that
Arg1 expression precedes that of IDO1 in DCs exposed to
TGF-b alone. Perhaps more importantly, these data unveiled that
the Arg and Trp catabolic pathways can be co-activated in DCs.
Arg1 Expression Is Required for IDO1 Induction by
TGF-b in DCs
To better appreciate the temporal relationship between Arg1 and
IDO1expressions inTGF-b-stimulatedDCs,weperformedamore
comprehensive kinetic analysis—i.e., from 0.5 to 72 hr of cytokineImmincubation—of transcripts coding for the
two amino-acid catabolic enzymes. The
results confirmed the earlier induction of
Arg1 (34 hr; Figures 1A and 2A) as
compared to Ido1 transcripts (1618 hr;
Figures 1A and 2A), as well as a higher
extent of Arg1 expression that peaked at
2448 hr (>7 fold increase as compared
to unstimulated cells) of TGF-b stimula-tion. Ido1expressiondidnot increasemore than3-fold (Figure2A).
Nevertheless, in agreement with our previous data (Pallotta et al.,
2011), the extent of Ido1 expression remained stable throughout
the experiment, i.e., up to 72 hr, after which DCs could no longer
be analyzed because of poor viability. Conversely, Arg1 tran-
scripts appeared to decrease from 72 hr onward.
The sequential expressions of Arg1 and Ido1 prompted us to
investigate whether Arg1 was required for IDO1 induction by
TGF-b in DCs. We examined Ido1 transcript amounts over time
using DCs purified from the spleens of Itgax-cre;Arg1fl/fl mice,
lacking Arg1 expression in CD11c+ (i.e., DCs) but not in
CD11b+ cells (Figure S1). We found that Arg1 deficiency abro-
gated Ido1 induction by TGF-b but not by IFN-g in DCs (Fig-
ure 2B). Analysis of IDO1 activity (Figure 2C) at 24 hr of TGF-b
or IFN-g stimulation also indicated that lack of Arg1 expression
in DCs allowed IFN-g but not TGF-b to upregulate IDO1. Thus
these data identified a cytokine milieu whereby DCs exploit
Arg1 expression to increase IDO1.
Orn Upregulates IDO1 in the Absence of Externally
Added TGF-b
At variancewith IDO1, which exerts immunoregulatory additional
effects also via signaling activity (Pallotta et al., 2014; Pallotta
et al., 2011; Volpi et al., 2016), Arg1-mediated mechanisms
have been shown to occur only via Arg catalytic degradation.
We thus investigated whether upregulation of Ido1 transcripts
in DCs by TGF-b could be modulated by Nu-hydroxy-nor-Arg
(nor-NOHA), an inhibitor of arginases. Pre-incubation with
50 mM or 100 mM nor-NOHA for 1 hr prior to the addition ofunity 46, 233–244, February 21, 2017 235
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Figure 3. Orn Induces IDO1 Expression and Activity in DCs
Kinetic analysis of Ido1 transcripts in WT DCs stimulated with TGF-b (A and B), Orn (B and C), and/or IFN-g (C) for different times (indicated) in the presence or
absence of nor-NOHA (100 mM for IFN-g), or medium with standard (i.e., 400 mM) or low (4–40 mM) Arg concentration (F).
Kinetic analysis of Ido1 transcripts in WT (D, E) or CD11cdnR (E) DCs stimulated with Orn in the presence (D) or absence (E) of TGF-b receptor inhibitors. No toxic
effects of inhibitors could be observed in DCs at the used concentration of 10 mM (data not shown).
In (A)–(F), data are normalized and presented as in Figure 1A.
(G) Kynurenine concentrations in supernatants of WT DCs stimulated with TGF-b in a standard medium (where not specified) or a medium with low Arg (4 mM), in
the presence or absence of nor-NOHA (100 mM) or Orn (100 mM).
*p < 0.05; **p < 0.01; ***p < 0.001 (stimulated samples versus untreated controls). All data are from one experiment representative of three (means ± SD of
triplicates).TGF-b significantly impaired the Ido1-inducing ability of the cyto-
kine (Figure 3A), indicating a functional role for Arg1 catalytic ac-
tivity in IDO1 modulation.236 Immunity 46, 233–244, February 21, 2017We next investigated whether Orn, an Arg1 product, was
involved in Ido1 upregulation. Incubation of DCs with Orn at 50
or 100 mM (Figure 3B) significantly increased Ido1 expression,
AB C
Figure 4. Orn Activates IDO1 Signaling and
Confers IDO1-Dependent Immunosuppres-
sive Properties in DCs
(A) Immunoblot analysis of phosphorylated IDO1
(pIDO1) and total IDO1 in cell lysates of DCs
incubated for different times with TGF-b or Orn
(100 mM).
(B) Real-time PCR analysis of Ptpn6 and Tgfb1
transcripts in WT DCs stimulated with TGF-b or
Orn (100 mM) or in Itgax-cre;Argfl/fl DCs stimulated
with TGF-b for 18 hr. Data are normalized and
presented as in Figure 1A. *p < 0.05 and **p < 0.01
(unpaired Student’s t test; cytokine- or Orn-
treated versus untreated samples).
(C) In vivo suppression of the activity of HY-pulsed
WT CD8 DCs into WT recipient mice, in combi-
nation with a minority fraction (5%) of CD8 DCs
from either WT or Ido1/mice with no condition-
ing (unt, untreated) or conditioned in vitro with
TGF-b or Orn (100 mM) for 24 hr; analysis of skin
reactivity of recipientmice to theelicitingpeptide at
15 days is presented as change in footpad weight.
**p < 0.01 and ***p < 0.001 (paired Student’s t test;
mean weight of experimental versus control foot-
pads). Data are from one experiment representa-
tive of two (A) or three (B and C; means ± SD of
triplicates in B and six samples in C).similar to what observed with the cytokine alone (Figure 3B). In
contrast, no modulatory effect in Ido1 expression could be
observed in DCs stimulated with IFN-g in the presence of the
Arg1 inhibitor or Orn, both at 100 mM (Figure 3C). To evaluate
whether autocrine and/or paracrine TGF-b could be involved in
the Ido1-upregulating effects of Orn, WT DCs were incubated
with the Arg metabolite for different times after a 1 hr pretreat-
ment with an inhibitor of TGF-b receptor signaling, namely
SB-431542, LY2109761, or LY2157299 (also known as galuni-
sertib) (Figure 3D). DCs purified from transgenic CD11cdnR
mice (expressing a truncated form of TGF-b receptor II subunit
in CD11c+ cells) (Laouar et al., 2005) were also assayed (Fig-
ure 3E). Both pharmacologic and genetic means of TGF-b
signaling inhibition indicated that Orn effects do require auto-
crine and/or paracrine effects of TGF-b in both early inducing
and late maintaining phase of Ido1 expression (see also Supple-
mental Text) and that the cytokine could be produced constitu-
tively by DCs in basal conditions, in accordance to our previous
data (Belladonna et al., 2008).
In contrast to Orn, media deficient in Arg (4 and 40 mM in the
place of standard 400 mM; Figure 3F) did not significantly
increased Ido1 expression. Moreover, Orn at 100 mM but not
the use of an Arg-deficient medium (i.e., Arg at 4 mM) significantly
increased IDO1 activity to an extent comparable to that
observed with TGF-b (Figure 3G). Therefore, our data indicated
that Orn, a main Arg1 product, but not Arg starvation, can condi-
tion DCs to upregulate IDO1 expression and activity if autocrine
and/or paracrine TGF-b is present.
Orn Confers Immunosuppressive Properties on DCs via
IDO1 Signaling
IDO1 immunosuppressive effects include non-enzymic func-
tions, namely intracellular signaling events that, initiated by
ITIM phosphorylation in the enzyme, are involved in reprogram-ming gene expression and in the induction of a stably regulatory
phenotype in DCs (Orabona et al., 2012; Pallotta et al., 2011),
capable of controlling T cell-mediated autoimmune responses
(Pallotta et al., 2014; Volpi et al., 2016). In particular, IDO1’s
ITIM phosphorylation is triggered in DCs by TGF-b via a pathway
that requires phosphatidylinositide 3-kinase (PI3K) and a tyro-
sine kinase of the Src family (Bessede et al., 2014; Volpi et al.,
2016), which phosphorylates IDO1 ITIMs. In turn, phosphory-
lated IDO1 ITIMswork as docking sites for tyrosine protein phos-
phatases, such as SHP-1 and SHP-2, which are concomitantly
upregulated by TGF-b (Orabona et al., 2012; Pallotta et al.,
2011). These events lead to the activation of an immunoregula-
tory signaling pathway in DCs that promotes endogenous pro-
duction of TGF-b and induction of the Ido1 gene, perpetuating
IDO1 signaling events and associated immunosuppressive ef-
fects over the long term.
Because Orn was capable of upregulating Ido1 in DCs in a
sustained fashion comparable to that of TGF-b (Figure 3), we
investigated whether Orn could replace the cytokine in activating
the IDO1’s signaling and immunosuppressive effects. By means
of an antibody specific for the phosphorylated form of the
enzyme (Bessede et al., 2014; Pallotta et al., 2011; Volpi et al.,
2016), we found that the DC incubation with Orn did induce
IDO1 phosphorylation, with a peak at 15min, i.e., an effect earlier
than that triggered by TGF-b (at 30–60 min) (Figure 4A). More-
over, similarly to TGF-b, stimulation with the Arg1 product upre-
gulated transcript expression of Ptpn6 (coding for SHP-1) and
Tgfb1 at 18 hr in WT DCs. In contrast, no or less upregulation
of Ptpn6 and Tgfb1, respectively, was induced by TGF-b in
Itgax-cre;Arg1fl/fl DCs (Figure 4B), further confirming the impor-
tant role of Arg1 in triggering and maintaining the IDO1 signaling.
To appreciate the immunosuppressive potential of DCs condi-
tioned by Orn, we used the skin test assay, an established pro-
tocol for measuring the in vivo induction of antigen-specificImmunity 46, 233–244, February 21, 2017 237
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Figure 5. Inhibition of Orn Decarboxylation
Abrogates Orn Effects in DCs
(A) Expression of Odc1 transcripts in sub-pop-
ulations of DCs derived from different tissues.
(B) Kinetic analysis of Ido1 transcripts in WT DCs
stimulated with Orn (100 mM) in the presence or
absence of 1 mM DFMO for different times (indi-
cated). Data are normalized and presented as in
Figure 1A. **p < 0.01 and ***p < 0.001 (unpaired
Student’s t test; Orn- or Orn plus DFMO-treated
versus untreated samples).
(C) In vivo suppression of the activity of HY-pulsed
WT CD8 DCs in combination with a minority
fraction (5%) of the same cells with no condition-
ing (untreated, unt) or conditioned in vitro with Orn
as in Figure 4C in the presence or absence of
DFMO (1 mM); analysis of skin reactivity is as in
Figure 4C. **p < 0.01 and ***p < 0.001 (paired
Student’s t test as in Figure 4C). Data are from one
experiment representative of three (B and C;
means ±SD of triplicates in B and six samples in C;
means ± SD of samples indicated in Table S3 for
each DC subset in A). Please see also Figures S2
and S3.immunoreactivity versus tolerance in DCs (Grohmann et al.,
2002; Grohmann et al., 2007; Pallotta et al., 2011; Puccetti
et al., 1994). To this purpose, we sensitized wild-type (WT)
mice with the HY peptide (containing the H-2Db epitope of
male minor transplantation antigen) presented by WT CD8
DCs (constituting an immunostimulatory, splenic DC subset)
(Grohmann et al., 2003a) administered alone or in combination
with aminority fraction of the same cells (5%) purified from either
WT or Ido1/ animals after conditioning with TGF-b, Orn, or me-
dium alone for 24 hr. After priming the mice, we assessed im-
mune reactivity at two weeks by intrafootpad challenge with
the HY peptide in the absence of DCs, as described (Grohmann
et al., 2002; Grohmann et al., 2007; Pallotta et al., 2011; Puccetti
et al., 1994). As expected, the default priming ability of immunos-
timulatory DCs was not affected by the presence of untreated
cells. Yet, sensitization together with TGF-b- but also Orn-pre-
treated WT DCs caused suppression of HY-specific reactivity,
an effect not detectable in mice sensitized with Ido1/ DCs,
regardless of whichever type of conditioning molecule had
been used (Figure 4C).
As a whole, our data indicated that the mere incubation of
DCs with an Arg metabolite can activate molecular events238 Immunity 46, 233–244, February 21, 2017traceable to IDO1 signaling as well
as IDO1-dependent immunosuppressive
outcomes detectable in vivo.
Orn Decarboxylation Is Required
for Orn Effects Mediated by IDO1
in DCs
Orn can be further metabolized into pu-
trescine, a polyamine that, in turn, can
be transformed into spermidine and
then spermine (Figure S2), by Orn decar-
boxylase (ODC). In tumor cells, where it is
often highly expressed, ODC favors pro-liferative events. More recently, ODC has been shown to be like-
wise involved in immunoregulatory mechanisms that oppose
anti-tumor immunity (Hayes et al., 2014). As a matter of fact,
administration of a-difluoromethylornithine (DFMO), an ODC in-
hibitor, will inhibit tumor growth via impairment of MDSC-medi-
ated suppressive effects (Ye et al., 2016). Whether DFMO-pro-
moted immunity might also depend on impairment of IDO1
activity in DCs is currently unknown.
To evaluate ODC expression in DCs, we conducted a meta-
analysis of public microarray data restricted to the expression
of the Odc1 gene in several mouse DC subsets purified from
both lymphoid and nonlymphoid organs. The results showed
that high amounts of Odc1 transcripts were detectable in all
DC subsets analyzed so far, including splenic, conventional
CD11c+ DCs, the subject of the current study (Figure 5A).
Prompted by these data, we investigated the effects of ODC in-
hibition on Orn actions in DCs. Because of the obligate require-
ment for ODC in many cell types (Cervelli et al., 2014; Guo et al.,
2005), we addressed this issue by using DFMO. We found that
co-incubation of splenic DCs with Orn and DFMO abrogated
the capacity of Orn alone to upregulate Ido1 expression (Fig-
ure 5B). Moreover, by using the skin test assay as in Figure 4C,
we found that no immunosuppressive effects could be conferred
by Orn on WT DCs upon co-incubation of cells with DFMO
(Figure 5C).
Because stimulation with Orn induced significant upregulation
of the IDO1 gene in human DCs as well, and DFMO negated this
effect (Figure S3), our data suggest that the ODC catalytic activ-
ity basally expressed in DCs exerts important immunoregulatory
effects and that metabolites downstream of ODC function might
represent the most proximal inducers of IDO1 signaling and
IDO1-mediated immunosuppression in DCs.
Spermidine Activates the Src Kinase and Confers
IDO1-Dependent, ImmunosuppressiveProperties inDCs
Polyamines, i.e., the diamine putrescine, the triamine spermi-
dine, and the tetra-amine spermine, are highly bioactive polyca-
tions capable of binding nucleic acids and proteins and of modu-
lating several signaling pathways. Polyamine functions have
been studied most extensively in tumors, where they are often
required for cell transformation and proliferation (Gerner and
Meyskens, 2004). Whether polyamines can be produced by, or
exert effects on, DCs is currently unknown.
Real-time PCR analyses revealed that DCs expressed high
amounts of Srm and Sms genes, coding for spermidine and
spermine synthase, respectively, and that such expression
was not modulated by either TGF-b or IL-4 (Figure S4A). To
evaluate the effective production of polyamines by DCs, we as-
sessed the profile of Arg metabolites along with that of Trp
over time in culture supernatants of cells incubated with Orn
(Figure 6A). Following Orn incubation, an increase was
observed in DC release of all polyamines, with putrescine
and spermidine production being evident at 4 hr and spermine
at 16 hr. Moreover, Orn incubation also led to upregulation of
IDO1 products, i.e., L-formylkynurenine at 4 hr, followed by
L-kynurenine at 16 hr. An increase in other Orn metabolites
(i.e., proline, 1-pyrroline 4-hydroxy-2-carboxylate, g-L-glu-
tamyl-putrescine, and g-L-glutamyl-amino-butyraldehyde) and
Trp metabolites (serotonin, tryptamine, 5-hydroxy-L-trypto-
phan, and indole-3-acetaldehyde) could also be observed
upon DC incubation with Orn.
We then compared the IDO1-inducing ability of polyamines
with that of Orn in DCs. The results showed that DC incubation
with either putrescine or spermidine for 24 hr significantly
increased expression of the Ido1 gene to an extent comparable
to those induced by Orn (Figure 6B), whereas induction of the
IDO1protein could be observed only for spermidine (Figure S4B).
In contrast, spermine did not upregulate IDO1 but rather showed
a tendency to downregulate the enzyme expression (Figure 6B
and S4). In pro-inflammatory microenvironments, IDO1 is sub-
jected to regulatory proteolysis mediated by the immunoprotea-
some in DCs (Orabona et al., 2008). We therefore investigated
whether lack of IDO1 protein upregulation by putrescine could
be due to a concomitant increase in immunoproteasome activity.
We found that putrescine but not spermidine significantly upre-
gulated Psmb8, Psmb9, and Psmb10 transcripts, coding for
b5i, b1i, and b2i immunoproteasome subunits, respectively, in
DCs (Figure S4C). Moreover, we analyzed IDO1 protein expres-
sion in lysates from DCs exposed to cycloheximide (an inhibitor
of protein synthesis) prior to incubation with putrescine alone or
in combination with MG132, a proteasome inhibitor. These re-sults revealed that, in the presence of cycloheximide, putrescine
alone rather promoted a reduction in IDO1 protein expression,
which was opposed by the co-presence of MG132 (Figure S4D).
The combination ofMG132 and putrescine was accompanied by
the appearance of proteins of higher molecular weight than
42 kDa, possibly representing polyubiquitinated IDO1 species,
as described (Orabona et al., 2008).
In tumor cells, putrescine and spermidine but not spermine
promote the phosphorylation and consequent activation of
MAPK, Src, and PI3K (normally followed by Akt) kinases, via still
undefined mechanisms (Ho¨ltt€a et al., 1993). Conversely, sper-
mine has been shown to restrain immune responses in activated
macrophages by inhibiting gene expression of NOS2 (Zhang
et al., 1997). In intestinal epithelial cells, spermine negatively
modulates the activity of Src kinase via direct binding of the
Src SH2 domain (Ray et al., 2012). Because Src is involved in
the activation of IDO1 signaling in DCs (Bessede et al., 2014; Pal-
lotta et al., 2011; Volpi et al., 2016), we evaluated the ability of
polyamines in modulating Src phosphorylation over time. Pu-
trescine and spermidine, but not spermine, increased Src phos-
phorylation in DCs, as soon as at 5 min of cell incubation (Fig-
ure 6C). To conduct a more comprehensive evaluation of the
potential of putrescine and spermidine in modulating signaling
pathways in DCs, we performed a kinomic analysis using a mi-
croarray of peptides phosphorylable by tyrosine, serine, and
threonine kinases (van Baal et al., 2006) and cell extracts from
DCs incubated with the polyamines for 15 or 30 min. We found
that putrescine is a potent activator of several kinases in DCs
(Figure S4E), including Src, Fyn, Hck, and Lck tyrosine kinases
(Table S1), and that it also promotes phosphorylation of a pep-
tide from IKKb, a kinase involved in the activation of the pro-in-
flammatory NF-kB pathway (Table S4). Although less potent
when considering the overall effect (Figure S4E), spermidine
did promote tyrosine phosphorylation of peptides from protein
kinase C (i type) and b-catenin, known substrates of Src and
Fyn kinases (Table S1), respectively, but not from IKKb (Ta-
ble S4).
In a skin test assay, DC incubation with spermidine (Figure 6D)
led to immunosuppressive effects detectable in vivo. Moreover,
as observed for Orn (Figure 4C), spermidine effects were lost in
Ido1/ DCs (Figure 6D). Importantly, the immunosuppressive
effects were also impaired by coincubatingWTDCswith spermi-
dine and PP2 (a Src kinase inhibitor) but not PP3 (a negative con-
trol) (Figure 6D).
Overall, our data suggest that spermidine and its metabolic
precursor putrescine are produced by DCs and represent major
modulators of their own signaling pathways and function,
including the activation of Src kinase. However, only spermidine
triggered immunosuppressive IDO1 signaling, an effect possibly
lost when using putrescine for DC conditioning because of the
concomitant activation of several kinases other than those
belonging in the Src family, including proinflammatory IKKb,
and because of the increased expression of proteasome sub-
units possibly degrading the IDO1 protein.
Arg1+ MDSCs Condition DCs toward an IDO1-
Dependent, Immunosuppressive Phenotype
As evident from their name, the defining feature ofMDSCs is their
ability to suppress immune cell functions. Main factorsImmunity 46, 233–244, February 21, 2017 239
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Figure 6. Spermidine Activates IDO1 Immunosuppressive Signaling
(A) Analysis of Arg and Trp metabolite profiles in culture supernatants from DCs incubated with Orn (100 mM) for 4 or 16 hr. Results are expressed in terms of
heatmap, in which each square represents the fold change in mass to charge ratio mean value of the relative metabolite as compared to time 0. Annotated
targeted metabolites were derived from nontarget raw date and only represent signals of established chemical identities with 5 ppm.
(B) Real-time PCR analysis of Ido1 transcripts in DCs incubated with Orn, putrescine (Put), spermidine (Spd), or spermine (Spm; all at 20 mM) or medium alone for
24 hr. Data are normalized and presented as in Figure 1A. *p < 0.05 and **p < 0.01 (unpaired Student’s t test; Orn- or polyamine-treated versus untreated
samples).
(C) Kinetics of Src phosphorylation in WT DCs incubated with Put, Spd, or Spm at 20 mM for different times. Cell lysates were analyzed by sequential immu-
noblotting with antibody to phosphorylated Src (pSrc), anti-Src, and b-tubulin.
(D) In vivo suppression assay with a minority fraction (5%) of WT or Ido1/ CD8 DCs with no conditioning (Unt) or conditioned in vitro with 20 mM spermidine in
the presence or absence of PP2 or PP3 at 5 mM; analysis of skin reactivity is as in Figure 4C. **p < 0.01 and ***p < 0.001 (paired Student’s t test as in Figure 4C).
Data are from one experiment representative of two (A) and three (B–D; means ± SD of triplicates in B and six samples in D). Please see also Figure S4.
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C). Please see also Figure S5.implicated in MDSC-mediated immune suppression include
high expression of Arg1, among others (Marvel and Gabrilovich,
2015). In addition to their inherent immunosuppressive
activity, MDSCs might amplify regulatory properties of other
immune cells, particularly in tumor microenvironments.
Although some mechanisms underlying MDSC-macrophage
interaction have been established (Ugel et al., 2015), the cross-
talk between MDSCs and DCs is still unclear (Ostrand-Rosen-
berg et al., 2012).
Prompted by the finding that an extracellular polyamine can
condition DCs toward an IDO1-dependent, immunosuppres-
sive phenotype, we investigated whether MDSCs could also
exert similar effects on DCs via the Arg1 pathway. Arg1+
MDSCs were obtained from the bone marrow of WT mice as
described (Youn et al., 2008), pre-treated with nor-NOHA,
DFMO (100 mM and 1 mM, respectively), or medium alone
for 1 hr, extensively washed, and cocultured with DCs in
separate chambers of transwells (Figure 7A). After 24 hr,
DCs were recovered and analyzed for Ido1 transcript expres-
sion by real-time PCR as well as immunosuppressive potential
in vivo by skin test assay as in Figure 4C and Figure 6D. Con-
trols included DCs cultured in transwells without MDSCs (me-
dium; Figure 7A). We found that the separate coculture with
untreated MDSCs significantly upregulated Ido1 expression
(Figure 7B) and conferred in vivo immunosuppressive proper-
ties on DCs (Figure 7C). However, both effects were lost when
either Arg1 or ODC catalytic activity had been inhibited in
MDSCs before their co-culturing with DCs. Moreover, no
in vivo immunosuppressive phenotype could be acquired byImmIdo1/ DCs by conditioning with
MDSCs not subjected to Arg1 or ODC
inhibitor treatment (Figure 7C).
Thus our data confirmed that Arg and
Trp immunoregulatory pathways are
functionally integrated and that this inte-gration can occur both intra- (i.e., DCs) and inter-cellularly
(MDSCs and DCs) (Figure S5A and Figure 7).
DISCUSSION
Aneffectivecommunicationnetworking represents thebasisof life
of evolved multicellular organisms. As a matter of fact, evidence
for critical cross-talk mechanisms between metabolism and im-
munity—the main systems involved in maintaining and defending
a constant internal milieu (Odegaard and Chawla, 2013; Pearce
and Pearce, 2013)—are emerging. In establishing adaptive immu-
nometabolic networks over evolution, functional repurposing of
ancestral proteins (originally only metabolic or immune in nature)
may have represented a powerful strategy. Such evolved struc-
tures—defined as ‘‘moonlighting proteins’’ when they maintain
their original function—oftenderive fromgeneduplication, amajor
driving force that renders biological systems more robust to envi-
ronmental perturbations (Espinosa-Cantu´ et al., 2015).
Immune regulation is a highly evolved form of biologic
response that controls immunity to self but also dampens exag-
gerated inflammation (Fazekas de St Groth, 1998; Flajnik and
Kasahara, 2010; Grohmann and Bronte, 2010). Metabolism of
Arg and Trp and their consequent starvation in cell microenviron-
ments still represent a survival strategy in phylogenetically
ancient organisms. Yet, Arg and Trp catabolisms have been
co-opted by immune regulation in mammals (Murray, 2016). In
this regard, the bulk of available information would suggest
that the Arg1 enzyme, known to catabolize Arg mainly in immune
cells such as MDSCs and macrophages, might have acquiredunity 46, 233–244, February 21, 2017 241
immunoregulatory functions by ‘‘simply’’ extending the ancient
mechanism of starvation to the control of activation and prolifer-
ation of T lymphocytes. This is even more true if one considers
that, for instance, mouse macrophages stimulated with IL-4
will upregulate Arg1 expression by 100- to 1,000-fold (Pauleau
et al., 2004). In contrast, in our study, the increase in Arg1 tran-
scripts in DCs incubated with IL-4 was no higher than 8-fold,
suggesting that the Arg1 function in DCs might be considerably
different as compared to the profound Arg starvation determined
by Arg1+ macrophages. Nevertheless, the co-presence of IL-4
and TGF-b further upregulated Arg1 transcripts more than
20-fold, suggesting that maximal expression of Arg catabolism
would require multiple signals in DCs. In contrast, IDO1, the
Trp catabolizing enzyme mainly operating in immune cells such
as DCs, has been shown to exert immunoregulatory effects via
Trp starvation but also via its catalytic products, i.e., kynure-
nines, and, perhaps most importantly, via a non-enzymic
signaling activity (Chen, 2011; Grohmann et al., 2003b; Puccetti
and Grohmann, 2007a). In fact, by means of its ITIM domains
(phosphorylable by Src tyrosine kinases activated in the pres-
ence of TGF-b), IDO1 establishes an intracellular signaling
network in DCs that leads to the long-term expression of Ido1 it-
self and subsequent, sustained control of adaptive immunity. At
variance with Arg1, mouse Ido1, and human IDO1 as well, might
be the result of duplication of the more ancient Ido2 (IDO2 in hu-
mans) gene, an Ido1 (IDO1) paralog characterized by low effi-
ciency in Trp degradation and inability to act as a signaling mole-
cule (Orabona et al., 2012; Yuasa et al., 2007). This represents
the successful repurposing of a very ancient enzyme. Trypto-
phan 2,3-dioxygenase (TDO), another ancient enzyme mainly
expressed in the liver and responsible for the degradation of
Trp entered by diet, does not contain ITIMs.
We here showed that, in the presence of TGF-b but not IL-4,
IFN-g, or combinations thereof, Arg1 and IDO1 expressions co-
exist in DCs. If anything, the co-presence of other cytokines
rather impaired the TGF-b upregulating action on both amino-
acid catabolizing enzymes, an effect possibly due the antago-
nistic effects of IL-4 (Musso et al., 1994) and IFN-g (Bronte and
Zanovello, 2005) (G. Natoli, personal communication) on Ido1
and Arg1 gene expressions, respectively. The apparently tran-
sient, yet intense, induction of Arg1 enzymatic activity by TGF-b
was mandatory for the subsequent IDO1 upregulation in terms
of both catalytic and signaling mechanisms. These Arg1 effects
were not mediated by Arg deprivation (as one might have ex-
pected, due to the poor or absent proliferative capacity of DCs)
but rather by its downstream enzymatic catabolites, namely,
the polyamine spermidine, generated downstream of decarbox-
ylation of Orn, one of the direct Arg1 catalytic products. More-
over, our data indicated that this polyamine can promote IDO1
phosphorylation and signaling events in DCs (Bessede et al.,
2014; Pallotta et al., 2011; Volpi et al., 2016), possibly via direct
activation of the Src kinase. Spermidine might therefore repre-
sent a two-sided node responsible for an intersection between
the immunometabolic pathways of Arg1 and IDO1. Perhaps
most importantly, this relaypathwaywouldallow the immunesys-
tem to translate an initial short-term (Arg1-mediated; typical of
early-acting MDSCs and regulatory macrophages; Goldszmid
et al., 2014) intoasustained regulatory response (via IDO1; typical
of long-termacting tolerogenicDCs;Morelli andThomson, 2007).242 Immunity 46, 233–244, February 21, 2017TGF-b is a cytokine that appeared in metazoans and, by virtue
of its marked pleiotropy and multiple effects, plays a prominent
role in the logic of communicative networks inmulticellular organ-
isms (Massague´ and Gomis, 2006). Although the output of a
TGF-b response is highly contextual, thepresenceof this cytokine
in microenvironments often favors local immunosuppression, in-
hibiting anti-tumor immunity (Gorelik and Flavell, 2002; Pickup
et al., 2013; Tu et al., 2014). The TGF-b potential for inducing
both enzymes, i.e., Arg1 in macrophages (Boutard et al., 1995)
and IDO1 in DCs (Belladonna et al., 2009; Pallotta et al., 2011)
was already known. However, we here demonstrated that the
immunoregulatory effects of TGF-b in DCs would go beyond the
mutually exclusive upregulation of the Arg1 and IDO1 enzymes
(observable in the presence of IL-4 and IFN-g, respectively) by al-
lowing the establishment of a network involving both Arg1 and
IDO1 in DCs, further underlining the functional plasticity of these
cells. Moreover, because MDSCs themselves are an abundant
source of TGF-b production (Bierie and Moses, 2010), the
network established by the triad constituted by TGF-b, Arg1,
and IDO1might be highly relevant to establishing potent immuno-
suppressive environments if also DCs are present as well.
In conclusion, our data, besides further underlining the impor-
tance of critical pathways linking metabolism and immunity in
multicellular animals, suggest that the appearance of a highly
evolved form of biologic response such as immune regulation
would rely on a network based on the co-option of two ancient
pathways, i.e., Arg and Trp catabolisms (Anderson et al., 2016)
as reinforced by TGF-b. A consequence of this could be that tu-
mors, considered to be the result of an evolutionary process (Bill-
aud and Santoro, 2011), have become particularly apt to co-opt
metabolic and immunosuppressive networks to propel their gen-
eration and progression. Thus our data might predict that the
simultaneous inhibition of two immune checkpoints such as
Arg1 (https://clinicaltrials.gov/show/NCT02903914) and IDO1
(Buque´ et al., 2016) could represent a successful strategy in tu-
mor immunotherapy.
EXPERIMENTAL PROCEDURES
Mice
Eight- to ten-week-old female C57BL/6 mice were obtained from Charles River
Breeding Laboratories. Ido1/micewere purchased fromThe JacksonLabora-
tory and bred at Charles River. To obtain Itgax-cre;Argfl/flmice (i.e., lacking Arg1
expression in CD11c+ cells), C57BL/6-Arg1tm1Pmu/J were bred to the strain
C57BL/6J-Tg (Itgax-cre,-EGFP)4097Ach/J (The Jackson Laboratory), with
inducibleCre recombinase expression in theCD11c+ cells (Figure S1). CD11cdnR
mice on C57/BL6 background (Laouar et al., 2005) were bred andmaintained at
the animal facility of the University of Michigan School of Medicine.
Isolation and Treatments of DCs and MDSCs
Splenic DCs were purified using CD11c MicroBeads (Miltenyi Biotec), as
described (Grohmann et al., 2002). Purity of DCs is detailed in Supplemental
Experimental Procedures. MDSCs were obtained from bone marrow cells,
as previously described (Youn et al., 2008). Details of MDSC purification and
treatments can be found in Supplemental Experimental Procedures. For all
in vitro studies, CD11c+ or CD8 DCs were cultured at 1 3 106 cells per well
in 24-well plates in Iscove’s Modified Dulbecco’s medium (IMDM, Thermo
Fisher Scientific) or, in selected experiments, in Dulbecco’s Modified Eagle
Medium (DMEM, Thermo Fisher Scientific), containing low or standard Arg
levels (4, 40, or standard 400 mM) and completed by adding L-asparagine
(120 mM) and L-lysine (790 mM). Recombinant human TGF-b (R&D System),
Orn, and polyamines were used at the final concentration of 20 ng/ml,
50–100 mM, and 20 mM, respectively. In specific experiments, DCswere condi-
tioned by co-culture for 24 hr with MDSCs (either such or pretreated for 1 hr
with inhibitors) using transwell cell culture inserts (Nunc).
Real-Time RT-PCR, Western Blotting, and Determination of Arg1
and IDO1 Catalytic Activity
All these procedures are detailed in Supplemental Experimental Procedures.
Arg1 protein expression was investigated in DCs by immunoblot with a goat
polyclonal anti-mouse Arg1 antibody (Abcam). IDO1 and pIDO1 expressions
were investigated with a rabbit monoclonal anti-mouse IDO1 antibody
(cv152) (Romani et al., 2008) or a rabbit polyclonal antibody to the phosphor-
ylated ITIM1 motif of IDO1 (Pallotta et al., 2011), respectively.
Immunization and Skin Test Assay
A skin test assay was used for measurements of major histocompatibility com-
plex class I–restricted delayed-type hypersensitivity (DTH) responses to the HY
peptide (WMHHNMDLI) inC57BL/6 female recipientmice, asdescribed (Pallotta
et al., 2011). For in vivo immunization, 33 105 peptide-loaded CD8DCs, com-
bined with a minority fraction (5%) of peptide-loaded C57BL/6 or Ido1/CD8
DCs, were injected subcutaneously into recipient mice. Two weeks later, a DTH
responsewasmeasured to intrafootpad challengewith theeliciting peptide, and
results were expressed as the increase in footpad weight of peptide-injected
footpads over that of vehicle-injected (internal control) counterparts. Theminor-
ity cell fraction, constituted by WT or Ido1/ CD8 DCs, was left untreated or
treated overnight with specific reagents as above.
Meta-analysis of DC Gene Expression Data, Metabolomic Analyses,
and Kinome Profiling Analyses
All these procedures are detailed in Supplemental Experimental Procedures.
Statistical Analyses
Unpaired Student’s t test was used for in vitro analyses, using at least three
values from 2–3 experiments per group, whereas for the skin test assay paired
Student’s t test was used (using at least six mice per group). Differences were
considered significant with p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.immuni.2017.01.005.
AUTHOR CONTRIBUTIONS
G.M., C. Volpi, and U.G. designed the study. P.P., C. Volpi, and U.G. super-
vised the study as a whole. G.M. performed themajority of in vitro experiments
and prepared most of the figures. R.B. and C.O. performed in vivo experi-
ments. M.T.P. and A.M. supervised IDO1 signaling experiments. E.A. per-
formed measurements of L-kynurenine. C. Vacca, M.L.B., A.I., F.F., Y.L., and
L.S. helped with some experiments. S.U. and V.B. performed measurements
of urea and supervised experiments with MDSCs. F.G. and L.Z. performed
and supervised, respectively, metabolomics analyses. A.V. and M.P. per-
formed and supervised, respectively, kinomic analyses. E.M.C.M. and S.B.
performed and supervised, respectively, meta-analyses of Odc1 expression.
U.G. wrote the manuscript.
ACKNOWLEDGMENTS
We thank Ioana M. Iamandii for statistical analyses. This work was supported
by the European Research Council (338954-DIDO; to U.G. and A.M.)
and in part by Ministero dell’Istruzione, Universita` e Ricerca, Italy (FIRB
RBAP11T3WB; to U.G., V.B., and S.B.).
Received: August 3, 2016
Revised: November 18, 2016
Accepted: December 21, 2016
Published: February 14, 2017REFERENCES
Anderson, D.P., Whitney, D.S., Hanson-Smith, V., Woznica, A., Campodonico-
Burnett, W., Volkman, B.F., King, N., Thornton, J.W., and Prehoda, K.E. (2016).
Evolution of an ancient protein function involved in organized multicellularity in
animals. eLife 5, e10147.
Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of
immunity. Nature 392, 245–252.
Belladonna, M.L., Volpi, C., Bianchi, R., Vacca, C., Orabona, C., Pallotta, M.T.,
Boon, L., Gizzi, S., Fioretti, M.C., Grohmann, U., and Puccetti, P. (2008).
Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by
IDO-competent dendritic cells. J. Immunol. 181, 5194–5198.
Belladonna, M.L., Orabona, C., Grohmann, U., and Puccetti, P. (2009).
TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol.
Med. 15, 41–49.
Bessede, A., Gargaro, M., Pallotta, M.T., Matino, D., Servillo, G., Brunacci, C.,
Bicciato, S., Mazza, E.M., Macchiarulo, A., Vacca, C., et al. (2014). Aryl hydro-
carbon receptor control of a disease tolerance defence pathway. Nature 511,
184–190.
Bierie, B., andMoses, H.L. (2010). Transforming growth factor beta (TGF-beta)
and inflammation in cancer. Cytokine Growth Factor Rev. 21, 49–59.
Billaud, M., and Santoro, M. (2011). Is Co-option a prevailing mechanism
during cancer progression? Cancer Res. 71, 6572–6575.
Boutard, V., Havouis, R., Fouqueray, B., Philippe, C., Moulinoux, J.P., and
Baud, L. (1995). Transforming growth factor-beta stimulates arginase activity
in macrophages. Implications for the regulation of macrophage cytotoxicity.
J. Immunol. 155, 2077–2084.
Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by
L-arginine metabolism. Nat. Rev. Immunol. 5, 641–654.
Buque´, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A., Fridman, W.H.,
Fucikova, J., Galon, J., Spisek, R., Tartour, E., et al. (2016). Trial Watch-
Small molecules targeting the immunological tumormicroenvironment for can-
cer therapy. OncoImmunology 5, e1149674.
Cervelli, M., Angelucci, E., Germani, F., Amendola, R., andMariottini, P. (2014).
Inflammation, carcinogenesis and neurodegeneration studies in transgenic
animal models for polyamine research. Amino Acids 46, 521–530.
Chen, W. (2011). IDO: more than an enzyme. Nat. Immunol. 12, 809–811.
Espinosa-Cantu´, A., Ascencio, D., Barona-Go´mez, F., and DeLuna, A. (2015).
Gene duplication and the evolution of moonlighting proteins. Front. Genet.
6, 227.
Fallarino, F., Grohmann, U., You, S., McGrath, B.C., Cavener, D.R., Vacca, C.,
Orabona, C., Bianchi, R., Belladonna, M.L., Volpi, C., et al. (2006). The com-
bined effects of tryptophan starvation and tryptophan catabolites down-regu-
late T cell receptor zeta-chain and induce a regulatory phenotype in naive
T cells. J. Immunol. 176, 6752–6761.
Fazekas de St Groth, B. (1998). The evolution of self-tolerance: a new cell
arises to meet the challenge of self-reactivity. Immunol. Today 19, 448–454.
Flajnik, M.F., and Kasahara, M. (2010). Origin and evolution of the adaptive im-
mune system: genetic events and selective pressures. Nat. Rev. Genet.
11, 47–59.
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as
regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.
Gerner, E.W., andMeyskens, F.L., Jr. (2004). Polyamines and cancer: old mol-
ecules, new understanding. Nat. Rev. Cancer 4, 781–792.
Goldszmid, R.S., Dzutsev, A., and Trinchieri, G. (2014). Host immune response
to infection and cancer: unexpected commonalities. Cell Host Microbe 15,
295–305.
Gorelik, L., and Flavell, R.A. (2002). Transforming growth factor-beta in T-cell
biology. Nat. Rev. Immunol. 2, 46–53.
Grohmann, U., and Bronte, V. (2010). Control of immune response by amino
acid metabolism. Immunol. Rev. 236, 243–264.
Grohmann, U., and Puccetti, P. (2015). The Coevolution of IDO1 and AhR in the
Emergence of Regulatory T-Cells in Mammals. Front. Immunol. 6, 58.Immunity 46, 233–244, February 21, 2017 243
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A.,
Candeloro, P., Belladonna, M.L., Bianchi, R., Fioretti, M.C., and Puccetti, P.
(2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3,
1097–1101.
Grohmann, U., Bianchi, R., Orabona, C., Fallarino, F., Vacca, C., Micheletti, A.,
Fioretti, M.C., and Puccetti, P. (2003a). Functional plasticity of dendritic cell
subsets as mediated by CD40 versus B7 activation. J. Immunol. 171,
2581–2587.
Grohmann, U., Fallarino, F., and Puccetti, P. (2003b). Tolerance, DCs and tryp-
tophan: much ado about IDO. Trends Immunol. 24, 242–248.
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C.,
Orabona, C., Belladonna, M.L., Ayroldi, E., Nocentini, G., et al. (2007).
Reverse signaling through GITR ligand enables dexamethasone to activate
IDO in allergy. Nat. Med. 13, 579–586.
Guo, Y., Cleveland, J.L., and O’Brien, T.G. (2005). Haploinsufficiency for odc
modifies mouse skin tumor susceptibility. Cancer Res. 65, 1146–1149.
Hayes, C.S., Burns, M.R., and Gilmour, S.K. (2014). Polyamine blockade pro-
motes antitumor immunity. OncoImmunology 3, e27360.
Ho¨ltt€a, E., Auvinen, M., and Andersson, L.C. (1993). Polyamines are essential
for cell transformation by pp60v-src: delineation of molecular events relevant
for the transformed phenotype. J. Cell Biol. 122, 903–914.
Laouar, Y., Sutterwala, F.S., Gorelik, L., and Flavell, R.A. (2005). Transforming
growth factor-beta controls T helper type 1 cell development through regula-
tion of natural killer cell interferon-gamma. Nat. Immunol. 6, 600–607.
Macagno, A., Napolitani, G., Lanzavecchia, A., and Sallusto, F. (2007).
Duration, combination and timing: the signal integration model of dendritic
cell activation. Trends Immunol. 28, 227–233.
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-
induced tolerance and immune suppression by myeloid derived suppressor
cells. Immunol. Rev. 222, 162–179.
Marvel, D., and Gabrilovich, D.I. (2015). Myeloid-derived suppressor cells in
the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125,
3356–3364.
Massague´, J., and Gomis, R.R. (2006). The logic of TGFbeta signaling. FEBS
Lett. 580, 2811–2820.
Mellor, A.L., and Munn, D.H. (2004). IDO expression by dendritic cells: toler-
ance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774.
Morelli, A.E., and Thomson, A.W. (2007). Tolerogenic dendritic cells and the
quest for transplant tolerance. Nat. Rev. Immunol. 7, 610–621.
Murray, P.J. (2016). Amino acid auxotrophy as a system of immunological con-
trol nodes. Nat. Immunol. 17, 132–139.
Musso, T., Gusella, G.L., Brooks, A., Longo, D.L., and Varesio, L. (1994).
Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human
monocytes. Blood 83, 1408–1411.
Odegaard, J.I., and Chawla, A. (2013). The immune system as a sensor of the
metabolic state. Immunity 38, 644–654.
Orabona, C., andGrohmann, U. (2011). Indoleamine 2,3-dioxygenase and reg-
ulatory function: tryptophan starvation and beyond. Methods Mol. Biol. 677,
269–280.
Orabona, C., Pallotta, M.T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R.,
Belladonna, M.L., Fioretti, M.C., Grohmann, U., and Puccetti, P. (2008).
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase
(IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci.
USA 105, 20828–20833.
Orabona, C., Pallotta, M.T., and Grohmann, U. (2012). Different partners,
opposite outcomes: a new perspective of the immunobiology of indoleamine
2,3-dioxygenase. Mol. Med. 18, 834–842.
Ostrand-Rosenberg, S., Sinha, P., Beury, D.W., and Clements, V.K. (2012).
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages,
and dendritic cells enhances tumor-induced immune suppression. Semin.
Cancer Biol. 22, 275–281.
Pallotta, M.T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M.L., Bianchi, R.,
Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011). Indoleamine244 Immunity 46, 233–244, February 21, 20172,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.
Nat. Immunol. 12, 870–878.
Pallotta, M.T., Orabona, C., Bianchi, R., Vacca, C., Fallarino, F., Belladonna,
M.L., Volpi, C., Mondanelli, G., Gargaro, M., Allegrucci, M., et al. (2014).
Forced IDO1 expression in dendritic cells restores immunoregulatory signal-
ling in autoimmune diabetes. J. Cell. Mol. Med. 18, 2082–2091.
Pauleau, A.L., Rutschman, R., Lang, R., Pernis, A., Watowich, S.S., and
Murray, P.J. (2004). Enhancer-mediated control of macrophage-specific argi-
nase I expression. J. Immunol. 172, 7565–7573.
Pearce, E.L., and Pearce, E.J. (2013). Metabolic pathways in immune cell acti-
vation and quiescence. Immunity 38, 633–643.
Pickup, M., Novitskiy, S., and Moses, H.L. (2013). The roles of TGFb in the
tumour microenvironment. Nat. Rev. Cancer 13, 788–799.
Platten, M., Wick, W., and Van den Eynde, B.J. (2012). Tryptophan catabolism
in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72, 5435–5440.
Puccetti, P., and Grohmann, U. (2007a). IDO and regulatory T cells: a role for
reverse signalling and non-canonical NF-kappaB activation. Nat. Rev.
Immunol. 7, 817–823.
Puccetti, P., Bianchi, R., Fioretti, M.C., Ayroldi, E., Uyttenhove, C., Van Pel, A.,
Boon, T., and Grohmann, U. (1994). Use of a skin test assay to determine tu-
mor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24, 1446–1452.
Ray, R.M., Li, C., Bhattacharya, S., Naren, A.P., and Johnson, L.R. (2012).
Spermine, a molecular switch regulating EGFR, integrin b3, Src, and FAK scaf-
folding. Cell. Signal. 24, 931–942.
Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D’Angelo, C., Zelante, T.,
Vacca, C., Bistoni, F., Fioretti, M.C., Grohmann, U., et al. (2008). Defective
tryptophan catabolism underlies inflammation in mouse chronic granuloma-
tous disease. Nature 451, 211–215.
Sica, A., and Mantovani, A. (2012). Macrophage plasticity and polarization:
in vivo veritas. J. Clin. Invest. 122, 787–795.
Tu, E., Chia, P.Z., and Chen,W. (2014). TGFb in T cell biology and tumor immu-
nity: Angel or devil? Cytokine Growth Factor Rev. 25, 423–435.
Ugel, S., De Sanctis, F., Mandruzzato, S., and Bronte, V. (2015). Tumor-
induced myeloid deviation: when myeloid-derived suppressor cells meet tu-
mor-associated macrophages. J. Clin. Invest. 125, 3365–3376.
van Baal, J.W., Diks, S.H., Wanders, R.J., Rygiel, A.M., Milano, F., Joore, J.,
Bergman, J.J., Peppelenbosch, M.P., and Krishnadath, K.K. (2006).
Comparison of kinome profiles of Barrett’s esophagus with normal squamous
esophagus and normal gastric cardia. Cancer Res. 66, 11605–11612.
Volpi, C., Mondanelli, G., Pallotta, M.T., Vacca, C., Iacono, A., Gargaro, M.,
Albini, E., Bianchi, R., Belladonna, M.L., Celanire, S., et al. (2016). Allosteric
modulation of metabotropic glutamate receptor 4 activates IDO1-dependent,
immunoregulatory signaling in dendritic cells. Neuropharmacology 102, 59–71.
Wu, G., and Morris, S.M., Jr. (1998). Arginine metabolism: nitric oxide and
beyond. Biochem. J. 336, 1–17.
Yang, Q., Wei, J., Zhong, L., Shi, M., Zhou, P., Zuo, S., Wu, K., Zhu, M., Huang,
X., Yu, Y., et al. (2015). Cross talk between histone deacetylase 4 and STAT6 in
the transcriptional regulation of arginase 1 duringmouse dendritic cell differen-
tiation. Mol. Cell. Biol. 35, 63–75.
Ye, C., Geng, Z., Dominguez, D., Chen, S., Fan, J., Qin, L., Long, A., Zhang, Y.,
Kuzel, T.M., and Zhang, B. (2016). Targeting Ornithine Decarboxylase by
a-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-
Derived Suppressor Cells. J. Immunol. 196, 915–923.
Youn, J.I., Nagaraj, S., Collazo, M., and Gabrilovich, D.I. (2008). Subsets of
myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181,
5791–5802.
Yuasa, H.J., Takubo, M., Takahashi, A., Hasegawa, T., Noma, H., and Suzuki,
T. (2007). Evolution of vertebrate indoleamine 2,3-dioxygenases. J. Mol. Evol.
65, 705–714.
Zhang, M., Caragine, T., Wang, H., Cohen, P.S., Botchkina, G., Soda, K.,
Bianchi, M., Ulrich, P., Cerami, A., Sherry, B., and Tracey, K.J. (1997).
Spermine inhibits proinflammatory cytokine synthesis in human mononuclear
cells: a counterregulatory mechanism that restrains the immune response.
J. Exp. Med. 185, 1759–1768.
